Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTCYNASDAQ:ICUNASDAQ:PAVMNASDAQ:VERO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTCYBiotricity$0.51$0.44$0.19▼$1.30$12.71M1.2237,467 shs1,684 shsICUSeaStar Medical$1.25+0.8%$1.56$1.11▼$13.85$12.25M-0.9261,865 shs117,034 shsPAVMPAVmed$0.67-0.8%$0.71$0.55▼$2.35$11.41M1.11116,803 shs153,639 shsVEROVenus Concept$2.41-0.4%$3.10$2.16▼$17.49$3.46M-0.03382,536 shs33,651 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTCYBiotricity0.00%+2.00%+34.21%+25.93%-58.02%ICUSeaStar Medical+0.81%-2.72%0.00%-36.22%-88.62%PAVMPAVmed-0.76%-15.50%-3.67%+7.68%-69.65%VEROVenus Concept+1.90%-2.03%-73.01%-38.28%-67.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTCYBiotricityN/AN/AN/AN/AN/AN/AN/AN/AICUSeaStar Medical0.4593 of 5 stars0.05.00.00.01.60.00.0PAVMPAVmed4.504 of 5 stars3.85.00.04.33.30.80.6VEROVenus Concept0.7436 of 5 stars0.02.00.00.02.73.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTCYBiotricity 2.00HoldN/AN/AICUSeaStar Medical 0.00N/AN/AN/APAVMPAVmed 3.50Strong Buy$19.502,820.91% UpsideVEROVenus Concept 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VERO, PAVM, ICU, and BTCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $19.50(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTCYBiotricity$12.06M1.05N/AN/A($1.30) per share-0.39ICUSeaStar Medical$135K90.77N/AN/A($6.29) per share-0.20PAVMPAVmed$3.00M3.81N/AN/A($3.35) per share-0.20VEROVenus Concept$64.83M0.05N/AN/A($2.43) per share-0.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTCYBiotricity-$14.09M-$1.08N/A∞N/A-80.42%N/A-188.47%6/25/2025 (Estimated)ICUSeaStar Medical-$26.23M-$7.78N/A∞N/AN/AN/A-627.49%5/14/2025 (Estimated)PAVMPAVmed-$64.18M-$2.25N/AN/AN/A602.97%N/A-92.36%5/15/2025 (Estimated)VEROVenus Concept-$37.25M-$77.35N/A∞N/A-74.62%N/A-47.46%5/15/2025 (Estimated)Latest VERO, PAVM, ICU, and BTCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PAVMPAVmed-$0.40N/AN/AN/A$0.02 millionN/A3/31/2025Q4 2024VEROVenus Concept-$10.0089-$11.23-$1.2211-$11.23$16.99 million$15.77 million3/27/2025Q4 2024ICUSeaStar Medical-$0.89-$0.90-$0.01-$0.90$0.15 million$0.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTCYBiotricityN/AN/AN/AN/AN/AICUSeaStar MedicalN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/AVEROVenus ConceptN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTCYBiotricityN/A0.230.10ICUSeaStar MedicalN/A0.540.54PAVMPAVmedN/A0.060.06VEROVenus Concept2.831.861.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTCYBiotricity3.89%ICUSeaStar Medical1.69%PAVMPAVmed19.93%VEROVenus Concept87.41%Insider OwnershipCompanyInsider OwnershipBTCYBiotricity10.10%ICUSeaStar Medical1.08%PAVMPAVmed11.30%VEROVenus Concept48.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTCYBiotricity4024.91 million22.08 millionOptionableICUSeaStar Medical29.80 million4.37 millionNot OptionablePAVMPAVmed9017.09 million9.82 millionOptionableVEROVenus Concept4101.42 million3.70 millionNot OptionableVERO, PAVM, ICU, and BTCY HeadlinesRecent News About These CompaniesContrasting Venus Concept (NASDAQ:VERO) & Integra LifeSciences (NASDAQ:IART)May 4, 2025 | americanbankingnews.comVenus Concept Raises a Total of Approximately $2.7 Million in Gross Proceeds from Previously Announced Registered Direct Offerings of Common StockApril 14, 2025 | globenewswire.comVenus Concept prices 386,700 shares at $4.06 in registered direct offeringApril 11, 2025 | markets.businessinsider.comVenus Concept Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesApril 11, 2025 | globenewswire.comVenus Concept Announces Closing of $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesApril 10, 2025 | globenewswire.comVenus Concept to sell 328,573 shares at $3.50 in registered direct offeringApril 9, 2025 | markets.businessinsider.comVenus Concept Shares Tripled On Wednesday: Here's What HappenedApril 9, 2025 | benzinga.comVenus Concept Announces $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesApril 9, 2025 | globenewswire.comVenus Concept Announces $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesApril 9, 2025 | globenewswire.comVenus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025April 7, 2025 | globenewswire.comVenus Concept announces $11M debt-to-equity exchange transactionApril 2, 2025 | markets.businessinsider.comVenus Concept Completes Debt-to-Equity Exchange with MadrynApril 2, 2025 | tipranks.comVenus Concept Announces $11 million Debt-to-Equity Exchange TransactionApril 1, 2025 | globenewswire.comVenus Concept Inc. (NASDAQ:VERO) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comVenus Concept reports Q4 EPS ($11.23) vs ($20.14) last yearApril 1, 2025 | markets.businessinsider.comVenus concept signals revenue stabilization as strategic shifts concludeMarch 31, 2025 | msn.comVenus Concept Inc. (VERO) Q4 2024 Earnings Conference Call TranscriptMarch 31, 2025 | seekingalpha.comVenus Concept Announces Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 31, 2025 | globenewswire.com5VERO : Earnings Outlook For Venus ConceptMarch 28, 2025 | benzinga.comVenus Concept Inc trading halted, news pendingMarch 4, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to BenefitNetflix’s Trillion-Dollar Baby Ambition: Realistic or Ridiculous?By Leo Miller | April 24, 2025View Netflix’s Trillion-Dollar Baby Ambition: Realistic or Ridiculous?3 High-Momentum Gold Stocks Surging on the Metals RallyBy Nathan Reiff | April 30, 2025View 3 High-Momentum Gold Stocks Surging on the Metals RallyVERO, PAVM, ICU, and BTCY Company DescriptionsBiotricity NASDAQ:BTCY$0.51 0.00 (0.00%) As of 05/9/2025 02:20 PM EasternBiotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.SeaStar Medical NASDAQ:ICU$1.25 +0.01 (+0.81%) As of 05/9/2025 03:59 PM EasternSeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.PAVmed NASDAQ:PAVM$0.67 -0.01 (-0.76%) As of 05/9/2025 03:50 PM EasternPAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.Venus Concept NASDAQ:VERO$2.41 -0.01 (-0.41%) As of 05/9/2025 03:54 PM EasternVenus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
